Trial Details
COMPLETEDBasic Information
| Clinical ID | c2695 |
|---|---|
| Identifier | NCT03099785 |
| Trial Title | Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Diarrhea-predominant Irritable Bowel Syndrome |
| Interventions | DRUG: Rifamycin SV 600mg t.i.d.|DRUG: Rifamycin SV b.i.d. + Placebo|DRUG: Placebo t.i.d. |
Participant Information
| Sponsor | Cosmo Technologies Ltd |
|---|---|
| City | Leuven |
| Country/Region | Belgium |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2017-12-18 |
|---|---|
| Primary Completion Date | 2020-09-11 |
| Completion Date | 2020-12-14 |